 | Up a level |
Rotger, M; Tegude, H; Colombo, S; Cavassini, M; Furrer, H; Décosterd, L; Blievernicht, J; Saussele, T; Günthard, H F; Schwab, M; Eichelbaum, M; Telenti, A; Zanger, U M (2007). Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clinical pharmacology & therapeutics, 81(4), pp. 557-66. New York, N.Y.: Nature Publishing Group 10.1038/sj.clpt.6100072
Colombo, S; Buclin, T; Décosterd, LA; Telenti, A; Furrer, H; Lee, BL; Biollaz, J; Eap, CB; Swiss, HIV Cohort Study (2006). Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical pharmacology & therapeutics, 80(4), pp. 307-18. New York, N.Y.: Nature Publishing Group 10.1016/j.clpt.2006.06.006
Colombo, S; Telenti, A; Buclin, T; Furrer, H; Lee, BL; Biollaz, J; Decosterd, LA; Swiss, HIV Cohort Study (2006). Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Therapeutic drug monitoring, 28(3), pp. 332-8. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/01.ftd.0000211807.74192.62
Colombo, S; Soranzo, N; Rotger, M; Sprenger, R; Bleiber, G; Furrer, H; Buclin, T; Goldstein, D; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and genomics, 15(9), pp. 599-608. London: Lippincott Williams & Wilkins 10.1097/01.fpc.0000172241.42546.d3
Rotger, M; Colombo, S; Furrer, H; Bleiber, G; Buclin, T; Lee, BL; Keiser, O; Biollaz, J; Décosterd, L; Telenti, A; Swiss, HIV Cohort Study (2005). Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and genomics, 15(1), pp. 1-5. London: Lippincott Williams & Wilkins
